Geron (GERN) Stock Price, News & Analysis $1.93 -0.14 (-6.76%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.88▼$2.0750-Day Range$1.74▼$2.0952-Week Range$1.68▼$3.84Volume4.90 million shsAverage Volume6.54 million shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/APrice Target$4.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Geron MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside146.1% Upside$4.75 Price TargetShort InterestBearish8.19% of Shares Sold ShortDividend StrengthN/ASustainability-3.05Upright™ Environmental ScoreNews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.35) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector485th out of 945 stocksPharmaceutical Preparations Industry216th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.75, Geron has a forecasted upside of 146.1% from its current price of $1.93.Amount of Analyst CoverageGeron has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.19% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Geron has recently decreased by 1.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -20.15% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -3.05. Previous Next 3.7 News and Social Media Coverage News SentimentGeron has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Geron this week, compared to 3 articles on an average week.Search Interest13 people have searched for GERN on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.MarketBeat Follows2 people have added Geron to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Geron is held by insiders.Percentage Held by Institutions65.44% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 9.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Geron Stock (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Stock News HeadlinesDecember 11, 2023 | finance.yahoo.comRecent uptick might appease Geron Corporation (NASDAQ:GERN) institutional owners after losing 13% over the past yearDecember 6, 2023 | finance.yahoo.comGeron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory MyelofibrosisDecember 11, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 4, 2023 | msn.comGeron shares rise after positive trial results of blood disorder candidateDecember 4, 2023 | seekingalpha.comGeron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull CaseDecember 4, 2023 | finance.yahoo.comGeron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDSNovember 29, 2023 | bizjournals.comPeninsula biotech looks to hire 50-60 reps in anticipation of first drug approvalNovember 28, 2023 | finance.yahoo.comGeron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of DirectorsDecember 11, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 21, 2023 | thestreet.comGeron (GERN) Stock Surges After FDA Removes Full Clinical Hold on Imetelstat ApplicationNovember 7, 2023 | finance.yahoo.comGeron to Participate at Upcoming Investor Conferences in NovemberNovember 3, 2023 | markets.businessinsider.comGeron’s Growth Prospects: Expanding Commercial Team, Imetelstat Development, and Financial StabilityNovember 3, 2023 | finance.yahoo.comGeron Corporation (NASDAQ:GERN) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | fool.comGeron (GERN) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | seekingalpha.comGeron Corporation 2023 Q3 - Results - Earnings Call PresentationNovember 2, 2023 | markets.businessinsider.comGeron Corporation Q3 Loss beats estimatesNovember 2, 2023 | finance.yahoo.comGeron Corporation Reports Business Highlights and Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comGeron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDSNovember 2, 2023 | finance.yahoo.comGeron Corp (GERN) Reports Q3 2023 Financial Results and Business HighlightsNovember 1, 2023 | benzinga.com4GERN : Geron Earnings PreviewOctober 31, 2023 | finance.yahoo.comTechne (TECH) Q1 Earnings and Revenues Miss EstimatesOctober 26, 2023 | finance.yahoo.comGeron to Announce Third Quarter 2023 Financial Results on November 2, 2023October 23, 2023 | seekingalpha.comGeron Corporation Stock: Another Buying OpportunitySeptember 29, 2023 | markets.businessinsider.comGeron Reports EMA Validation Of Marketing Authorization Application For ImetelstatSeptember 29, 2023 | finance.yahoo.comGeron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDSSeptember 13, 2023 | msn.comGoldman Sachs Upgrades Geron (GERN)September 12, 2023 | msn.comGeron Corporation: The FDA, Catalysts And New Competition From Old DrugsSee More Headlines Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/11/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+144.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,900,000.00 Net Margins-55,138.49% Pretax Margin-55,138.49% Return on Equity-70.26% Return on Assets-48.43% Debt Debt-to-Equity Ratio0.10 Current Ratio3.75 Quick Ratio3.75 Sales & Book Value Annual Sales$600,000.00 Price / Sales1,755.89 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book9.70Miscellaneous Outstanding Shares543,060,000Free Float526,229,000Market Cap$1.05 billion OptionableOptionable Beta0.79 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. John A. Scarlett M.D. (Age 72)Chairman of the Board, President & CEO Comp: $1.53MDr. Andrew J. Grethlein (Age 59)Executive VP & COO Comp: $847.2kMs. Michelle J. Robertson (Age 56)Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Ms. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsMr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryMs. Shannon OdamVice President of Human ResourcesMs. Melissa A. Kelly Behrs (Age 59)Executive VP of Business Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 53)Executive VP of Corporate Strategy & Chief Commercial Officer Comp: $654.89kMr. Edward E. Koval (Age 61)Executive VP & Chief Business Officer Dr. Faye Feller M.D. (Age 41)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTCelldex TherapeuticsNASDAQ:CLDXOrganogenesisNASDAQ:ORGOAgenusNASDAQ:AGENLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsCitigroup Inc.Bought 276,572 shares on 12/6/2023Ownership: 0.148%Wellington Management Group LLPBought 342,493 shares on 12/1/2023Ownership: 1.916%Deutsche Bank AGBought 36,001 shares on 11/24/2023Ownership: 0.045%Walleye Capital LLCBought 1,322,938 shares on 11/21/2023Ownership: 0.410%Wolverine Trading LLCSold 10,100 shares on 11/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions GERN Stock Analysis - Frequently Asked Questions Should I buy or sell Geron stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price target for 2024? 3 brokers have issued 12 month price objectives for Geron's shares. Their GERN share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 146.1% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2023? Geron's stock was trading at $2.42 at the beginning of 2023. Since then, GERN shares have decreased by 20.2% and is now trading at $1.93. View the best growth stocks for 2023 here. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our GERN earnings forecast. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.14 million. Geron had a negative net margin of 55,138.49% and a negative trailing twelve-month return on equity of 70.26%. What ETFs hold Geron's stock? ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), WisdomTree BioRevolution Fund (WDNA), Range Cancer Therapeutics ETF (CNCR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). Who are Geron's major shareholders? Geron's stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (8.51%), MPM Bioimpact LLC (1.97%), Wellington Management Group LLP (1.92%), FMR LLC (1.39%), Northern Trust Corp (0.99%) and Invesco Ltd. (0.84%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:GERN) was last updated on 12/11/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.